Rep. Robert Bresnahan, Jr. Sells Off Shares of HCA Healthcare, Inc. (NYSE:HCA)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of HCA Healthcare, Inc. (NYSE:HCA). In a filing disclosed on March 27th, the Representative disclosed that they had sold between $1,001 and $15,000 in HCA Healthcare stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
• Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
• Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
• Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.

HCA Healthcare Price Performance

HCA traded down $0.09 during trading on Friday, hitting $342.25. 1,114,475 shares of the stock traded hands, compared to its average volume of 1,345,910. The business has a 50 day moving average price of $324.53 and a 200 day moving average price of $341.56. The company has a market cap of $84.26 billion, a price-to-earnings ratio of 15.58, a PEG ratio of 1.10 and a beta of 1.68. HCA Healthcare, Inc. has a twelve month low of $289.98 and a twelve month high of $417.14. The company has a debt-to-equity ratio of 69.07, a current ratio of 1.08 and a quick ratio of 0.97.

HCA Healthcare (NYSE:HCA) last posted its earnings results on Friday, January 24th. The company reported $6.22 EPS for the quarter, topping analysts’ consensus estimates of $6.03 by $0.19. HCA Healthcare had a net margin of 8.16% and a return on equity of 586.47%. During the same period in the previous year, the company earned $5.90 earnings per share. Equities research analysts forecast that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 17th will be issued a $0.72 dividend. This is a positive change from HCA Healthcare’s previous quarterly dividend of $0.66. This represents a $2.88 annualized dividend and a yield of 0.84%. The ex-dividend date is Monday, March 17th. HCA Healthcare’s dividend payout ratio (DPR) is currently 13.11%.

Insider Activity at HCA Healthcare

In related news, SVP Jennifer Berres sold 9,533 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $322.59, for a total value of $3,075,250.47. Following the transaction, the senior vice president now directly owns 15,412 shares in the company, valued at approximately $4,971,757.08. This represents a 38.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Bank of America cut their price target on HCA Healthcare from $380.00 to $370.00 and set a “buy” rating on the stock in a research note on Monday, January 27th. Cantor Fitzgerald restated an “overweight” rating and issued a $405.00 price target on shares of HCA Healthcare in a research report on Monday, January 27th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $380.00 price objective on shares of HCA Healthcare in a report on Tuesday, December 17th. Barclays reduced their price target on HCA Healthcare from $392.00 to $366.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Finally, Royal Bank of Canada cut their price objective on HCA Healthcare from $405.00 to $384.00 and set an “outperform” rating on the stock in a research note on Monday, January 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $385.67.

Institutional Investors Weigh In On HCA Healthcare

Institutional investors have recently added to or reduced their stakes in the company. Sanders Capital LLC raised its stake in HCA Healthcare by 1.0% in the 4th quarter. Sanders Capital LLC now owns 11,655,563 shares of the company’s stock valued at $3,498,417,000 after acquiring an additional 116,826 shares during the period. First Eagle Investment Management LLC raised its holdings in HCA Healthcare by 0.5% during the 4th quarter. First Eagle Investment Management LLC now owns 4,503,849 shares of the company’s stock valued at $1,351,830,000 after acquiring an additional 23,177 shares during the period. Geode Capital Management LLC grew its position in shares of HCA Healthcare by 1.3% in the fourth quarter. Geode Capital Management LLC now owns 3,871,057 shares of the company’s stock valued at $1,159,882,000 after purchasing an additional 50,321 shares in the last quarter. FMR LLC boosted its stake in HCA Healthcare by 322.3% in the 3rd quarter. FMR LLC now owns 3,141,769 shares of the company’s stock worth $1,276,909,000 after purchasing an additional 2,397,883 shares during the period. Finally, Capital World Investors increased its position in shares of HCA Healthcare by 0.7% during the fourth quarter. Capital World Investors now owns 2,928,452 shares of the company’s stock valued at $878,975,000 after buying an additional 19,121 shares during the period. 62.73% of the stock is owned by institutional investors.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.